Literature DB >> 28131927

Clinical Course and Monitoring Parameters After Continuous Interventional Intra-Arterial Treatment in Patients with Refractory Cerebral Vasospasm.

Christian von der Brelie1, Alexander Doukas2, Anja Stopfer2, Naomi Larsen2, Maximilian Mehdorn2, Michael Synowitz2, Olav Jansen2.   

Abstract

BACKGROUND: In aneurysmal subarachnoid haemorrhage cerebral vasospasm leads to clinical worsening and poor outcome. Interventional treatment with nimodipine might be a therapeutic option.
OBJECTIVE: To evaluate the clinical course of patients with different interventional treatment types.
METHODS: A retrospective, observational analysis was performed. Inclusion criteria were aneurysmal subarachnoid haemorrhage, clinical and/or radiologic evidence of vasospasm and interventional intra-arterial treatment. Patients were divided into 3 groups: continuous nimodipine infusion, repetitive nimodipine infusions, and singular nimodipine infusion. Pre- and postinterventional parameters were analyzed to evaluate the efficacy of the procedure in terms of responder status. Outcome was determined using the modified Rankin scale.
RESULTS: A total of 163 interventions (97 patients) were examined. Patients with continuous treatment showed a greater World Federation of Neurological Surgeons grade. Response to intra-arterial nimodipine in the continuous group was comparatively worse. Transcranial Doppler monitoring as well as brain tissue oxygenation measuring showed good correlation with imaging results. The rate of intraprocedural complications in the continuous treatment group was significantly greater. We observed a worse clinical outcome in the patients who underwent continuous treatment. None of the patients in the continuous group achieved favorable outcome after 3 months.
CONCLUSIONS: Facing the poor clinical outcome and the greater complication rate, continuous intra-arterial infusion of nimodipine in patients with angiographically refractory cerebral vasospasm has to be indicated strictly. Transcranial Doppler and brain tissue oxygenation monitoring seem to be reliable tools for evaluation of the clinical postinterventional course.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiographically refractory vasospasm; Cerebral vasospasm; Interventional therapy; Outcome; Subarachnoid hemorrhage

Mesh:

Substances:

Year:  2017        PMID: 28131927     DOI: 10.1016/j.wneu.2016.12.110

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  5 in total

1.  Adverse Events and Complications in Continuous Intra-arterial Nimodipine Infusion Therapy After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Thomas Kapapa; Ralph König; Benjamin Mayer; Michael Braun; Bernd Schmitz; Silwia Müller; Julia Schick; Christian Rainer Wirtz; Andrej Pala
Journal:  Front Neurol       Date:  2022-02-18       Impact factor: 4.003

2.  Continuous Intraarterial Nimodipine Infusion for the Treatment of Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage: A Retrospective, Single-Center Cohort Trial.

Authors:  Andreas Kramer; Moritz Selbach; Thomas Kerz; Axel Neulen; Marc A Brockmann; Florian Ringel; Carolin Brockmann
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

3.  The Local Intraarterial Administration of Nimodipine Might Positively Affect Clinical Outcome in Patients with Aneurysmal Subarachnoid Hemorrhage and Delayed Cerebral Ischemia.

Authors:  Johannes Walter; Martin Grutza; Markus Möhlenbruch; Dominik Vollherbst; Lidia Vogt; Andreas Unterberg; Klaus Zweckberger
Journal:  J Clin Med       Date:  2022-04-05       Impact factor: 4.241

Review 4.  Multimodality Monitoring for Delayed Cerebral Ischemia in Subarachnoid Hemorrhage: A Mini Review.

Authors:  Collin Labak; Berje Haroutuon Shammassian; Xiaofei Zhou; Ayham Alkhachroum
Journal:  Front Neurol       Date:  2022-04-13       Impact factor: 4.086

5.  Does Nimodipine, a Selective Calcium Channel Blocker, Impair Chondrocyte Proliferation or Damage Extracellular Matrix Structures?

Authors:  Necati Kaplan; Ibrahim Yilmaz; Numan Karaarslan; Yasin E Kaya; Duygu Y Sirin; Hanefi Ozbek
Journal:  Curr Pharm Biotechnol       Date:  2019       Impact factor: 2.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.